Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma

In a conceptual study of drug resistance we have used a preclinical model of malignant B-cell lines by combining drug induced growth inhibition and gene expression profiling. In the current report a melphalan resistance profile of 19 genes were weighted by microarray data from the MRC Myeloma IX tri...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2013-12, Vol.8 (12), p.e83252
Hauptverfasser:	Bøgsted, Martin, Bilgrau, Anders E, Wardell, Christopher P, Bertsch, Uta, Schmitz, Alexander, Bødker, Julie S, Kjeldsen, Malene K, Goldschmidt, Hartmut, Morgan, Gareth J, Dybkaer, Karen, Johnsen, Hans E
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Analysis Antineoplastic Agents - pharmacology B-Lymphocytes - drug effects B-Lymphocytes - metabolism B-Lymphocytes - pathology Cancer genetics Cancer therapies Cell Line, Tumor Chondroitin sulfate Clinical trials Combination drug therapy Cyclin D Cyclin D - genetics Cyclin D - metabolism DNA microarrays Drug resistance Drug Resistance, Neoplasm - genetics Drug screening Female Functional analysis Gene Expression Gene Expression Profiling Genes Hematology Heparan sulfate High resistance High-Throughput Screening Assays Hospitals Humans Independent variables Internal medicine Kinases Lymphocytes B Male Medical diagnosis Medical research Medical screening Melphalan Melphalan - pharmacology Middle Aged Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - genetics Multiple Myeloma - mortality Multiple Myeloma - pathology Multivariate analysis Neoplasm Proteins - genetics Neoplasm Proteins - metabolism Science Studies Survival Survival Analysis Translocation Translocation, Genetic
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!